Phase 2 Lung Cancer Trial, Not Yet Recruiting NCT07632209 Sponsor: Yayi He Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Not Yet Recruiting

NCT07632209
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged 18 to 75 years, of any gender.
  • People who have been diagnosed with small cell lung cancer (a type of lung cancer) confirmed by laboratory testing of tissue or cells, and whose cancer is classified as "extensive-stage" (meaning it has spread beyond one lung).
  • People who have already received at least two different courses of cancer treatment.
  • People who have at least one tumour that can be measured on a scan, according to standard measurement guidelines.
  • People whose physical functioning is rated as fully active or able to carry out light work (rated 0 or 1 on a standard oncology scale).
  • People whose blood counts, liver, kidney, and clotting function all meet minimum levels as assessed by blood tests (confirm with trial site for specific values).
  • People whose doctors estimate they are likely to live for at least 3 more months.
  • People who are willing to sign a consent form and are able to follow the study schedule and attend follow-up appointments.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have previously been treated with lomustine, anlotinib, or similar medicines that target blood vessel growth in tumours.
  • People whose cancer has spread to the brain and is not well controlled, is causing symptoms, or requires ongoing steroid treatment to manage it.
  • People who have active bleeding, a high risk of bleeding, a history of major bleeding in the gut or brain in the past 6 months, or wounds or ulcers that have not healed.
  • People with high blood pressure that cannot be controlled with medication, or who have had a heart attack, severe irregular heartbeat, or heart failure in the past 6 months.
  • People with an active infection (such as pneumonia or a blood infection) or a serious ongoing illness that is not well controlled, such as diabetes or an autoimmune condition.
  • People who are pregnant or breastfeeding; women in the trial must use effective contraception during treatment and for 6 months after the last dose, and men must use effective contraception during treatment and for 3 months after the last dose.
  • People who have had another type of cancer in the past 5 years, except for certain cancers that have been fully cured (such as a specific type of skin cancer or early-stage cervical cancer).
  • People who have a known allergy to lomustine, anlotinib, or any of the ingredients in these medicines.
  • People who have any other condition that the trial doctor considers would make participation unsuitable, such as a mental health condition or inability to attend follow-up visits.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Yayi He
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
1 June 2028

Primary endpoints

Objective Response Rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov